Japanese drugmakers Towa Pharmaceutical, Sawai Pharmaceutical and Nichi-iko Pharmaceutical have jointly announced the formation of a basic agreement to set standards for generic products, reports JCNNetwork.
On March 10, the Ministry of Health, Labor and Welfare requested that pharmaceutical manufacturers obtain appropriate approval and complete proscribed procedures for the National Health Insurance price listing by the end of 2011. In response to this, the three companies say they will strive to set appropriate standards for the joint development and approval of generic products. They aim to ensure a stable supply of generic products and promote their wide use by consumers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze